Latest news
Biocon announces commercial launch of Yesafili in USA - The Pharma LetterThe Pharma Letter · Fri, 07 Aug 2026 18:16:32 GMTBiocon expects stronger second half on new biosimilar launches - CNBC TV18CNBC TV18 · Thu, 06 Aug 2026 11:42:04 GMTEyePoint Completes Enrollment in Two Phase 3 Trials Evaluating Duravyu for DME - Eyewire+Eyewire+ · Wed, 05 Aug 2026 18:46:05 GMTBiocon Launches Yesafili in US, Eyes H2 Growth With Existing Contracts - scanx.tradescanx.trade · Wed, 05 Aug 2026 02:59:22 GMTBiocon Launches Yesafili™ Biosimilar for Eye Diseases in the US - Machine MakerMachine Maker · Tue, 04 Aug 2026 12:14:26 GMTBiocon debuts aflibercept biosimilar in US - ET PharmaET Pharma · Tue, 04 Aug 2026 09:54:14 GMTBiocon launches interchangeable biosimilar Yesafili for retinal diseases in US market - Indian Pharma PostIndian Pharma Post · Tue, 04 Aug 2026 06:21:06 GMTBiocon launches aflibercept biosimilar Yesafili - HealioHealio · Mon, 03 Aug 2026 18:55:16 GMT